VuEssence

Health Care · Molecular Diagnostics

Overview

VuEssence is focused on creating molecular diagnostic solutions to aid in the detection, management and understanding of disease. We rely on utilizing advanced technologies designed to decipher the human genome and transcription.

Funding and backers

Total raised
$3.8M
4 rounds on record
Latest round
$48k
Venture round · Apr 2025 · 18 mo ago
Team
11-50
employees, estimated range
The money's age
Due for its next round
18 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 25, 2025 Raised a round Venture round $48k · SEC Form D Dec 31, 2019 Raised a round Venture round $1.1M · SEC Form D Mar 15, 2018 Raised a round Venture round $1.5M · SEC Form D May 18, 2016 Raised a round Venture round $1.2M · SEC Form D
Funding rounds
RoundDateAmountInvestorsSource
Venture round Apr 2025 $48k — SEC Form D
Venture round Dec 2019 $1.1M — SEC Form D
Venture round Mar 2018 $1.5M — SEC Form D
Venture round May 2016 $1.2M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity VuEssence, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Maha SallamExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
SFC Capital
backs Llusern Scientific Limited logo
BGF
backs Cyted Health
Norwest Venture Partners
backs Nanopath
50 Partners
backs En Carta
Ideaspring Capital
backs Tvaster Genkalp
Beacon Angels
backs AmplifiDx
Similar startupsby what they do, their industry and backers
ElipticaVenture round · 2 yr ago · Founded 2022 · 1-10 employees
Eliptica is building an AI-powered molecular diagnostics platform using population-scale proteomics to enable earlier disease detection…
Llusern Scientific Limited logo51-200 employees
Llusern Scientific is a UK diagnostics company developing treatment-directing diagnostics that bring rapid molecular testing closer to the…
En CartaVenture round $6.2M · 4 mo ago · 11-50 employees
En Carta Diagnostics develops molecular tests, as easy to use as rapid tests, as precise as a PCR machine. We currently offer Lyme disease…
AmplifiDxVenture round $329k · 5 yr ago · Founded 2020 · 1-10 employees
The Might of Molecular. Fast & Accurate Results*.
NanopathSeries B $25M · this month · Founded 2019 · 51-200 employees · 7 roles
Nanopath has developed deep technological breakthroughs that have the potential to change the molecular diagnostic paradigm.
Tvaster Genkalp
Combining the power of liquid biopsy and AI-driven epigenetics, we deliver accurate cancer detection. Our approach transforms diagnostics…

Financials

Total raised
$3.8M
Latest round
Venture - Series Unknown
Funding rounds
4
Funding rounds
Round Announced Amount
Venture - Series Unknown 2025 $48k Details
Venture - Series Unknown 2019 $1.1M Details
Venture - Series Unknown 2018 $1.5M Details
Venture - Series Unknown 2016 $1.2M Details

People

Maha Sallam
Executive Officer, Director
SEC Form D
Lorne Thomas
Director
SEC Form D
Virginia Cates
Director
SEC Form D
Jeffrey Barnes
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Odessa United States
HQ
10-50 est. staff